Women’s Heart Health Expansion Act of 2026
Summary
The Women's Heart Health Expansion Act reauthorizes the WISEWOMAN program with $250M authorized over FY2027-2031 for cardiovascular screenings. The bill is in committee with bipartisan support, but actual funding requires separate appropriations. Diagnostic lab companies $DGX and $LH may see modest incremental revenue from grant-funded screening volume.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Bill reauthorizes WISEWOMAN program with $250M authorized over 5 years for cardiovascular screenings.
- 2.Authorization only; actual funding requires separate appropriations bills.
- 3.Diagnostic lab companies $DGX and $LH are the most directly positioned beneficiaries, but revenue impact is small (<0.2% of revenue).
Market Implications
The bill's low authorization amount and early legislative stage mean no immediate market catalyst. Diagnostic lab stocks ($DGX, $LH) are structurally positioned to capture incremental screening volume if appropriations follow, but the impact is negligible relative to their overall revenue. No real market data is available to cite price movements.
Full Analysis
The Women's Heart Health Expansion Act of 2026 (S.3944) was introduced on February 26, 2026 by Sen. Alsobrooks (D-MD) with original cosponsor Sen. Britt (R-AL). Hearings were held on March 19, 2026 in the Senate HELP Committee. The bill amends the Public Health Service Act to reauthorize the WISEWOMAN program, which provides supplemental grants for preventive health services including blood pressure, cholesterol, and obesity screenings for women. It authorizes $250 million for fiscal years 2027 through 2031.
The money trail: This is an authorization bill, not an appropriation. It sets a spending ceiling of $250M over five years, but actual funding depends on annual appropriations bills. The grants flow to entities already receiving breast and cervical cancer screening grants (section 1501) and other health care entities designated by the Secretary. These entities will purchase laboratory testing services from companies like Quest Diagnostics ($DGX) and LabCorp ($LH) to perform the screenings. The annual authorization of $50M is small relative to the $10B+ revenues of these diagnostic companies, so revenue impact is minimal.
Structural winners: Diagnostic lab companies are the most direct beneficiaries as they provide the blood work and lipid panels required. Hospital systems ($HCA) and health insurers ($UNH) may see downstream benefits from earlier detection, but the link is weaker. No pure-play women's health screening companies are publicly traded at scale.
Timeline: The bill is at hearing/markup stage. It must pass the Senate HELP Committee, then the full Senate, then the House (no companion bill yet), and be signed by The President. Given bipartisan sponsorship and the program's existing authorization, passage is plausible but not imminent. Actual market impact will only materialize after appropriations are passed, likely in FY2027.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Authorizes supplemental grants for preventive health services including blood pressure, cholesterol, and obesity screenings under the WISEWOMAN program.
Who must act
Recipients of grants under section 1501 of the Public Health Service Act (state and local health departments, community health centers) that apply for supplemental grants.
What happens
Increased demand for laboratory diagnostic testing services (blood panels, lipid profiles) from grant-funded screening projects.
Stock impact
Quest Diagnostics provides clinical lab testing services; incremental revenue from increased screening volume under the program, estimated at $5M-$20M annually (less than 0.2% of total revenue).
What the bill does
Same as above: authorizes grants for preventive health services including screenings.
Who must act
Same grant recipients as above.
What happens
Increased demand for laboratory diagnostic testing services from grant-funded screening projects.
Stock impact
LabCorp provides clinical lab testing services; incremental revenue from increased screening volume under the program, estimated at $5M-$20M annually (less than 0.2% of total revenue).
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
A bill to amend title XI of the Social Security Act to establish a payment model to reimburse providers for furnishing comprehensive breast cancer risk assessments and developing personalized screening and risk-reduction plans, and for other purposes.
To amend title XXVII of the Public Health Service Act and title XIX of the Social Security Act to require coverage of Alzheimer's biomarker testing under group health plans, group and individual health insurance coverage, and the Medicaid program.
ALERT Communities Act
Precision Brain Health Research Act of 2026
EVEST Act
Saving Lives and Reducing Health Care Waste by Improving Diagnosis in Medicine Act
Colorectal Cancer Early Detection Act
Efficiency Adjustment Delay Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →